Epidemiological Study in FRONtoTemporal Dementia

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05075187

Acronym

EFRONT

Enrollment

2287

Registered

2021-10-12

Start date

2021-09-01

Completion date

2024-01-09

Last updated

2026-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Frontotemporal Dementia

Brief summary

An international, multicenter, epidemiological observational study aims to investigate the prevalence of genetic etiologies in patients diagnosed with FTD or clinically suspected for FTD.

Detailed description

Frontotemporal dementia (FTD) is a genetically and pathologically heterogeneous neurodegenerative disease caused by the loss or damage of nerve cells in the brain's frontal and temporal lobes. This leads to abnormalities in behaviour, personality, and language comprehension problems. Also, people with FTD show movement disorders like tremor, rigidity, difficulty in coordination, muscle spasms and weakness. FTD's etiology is sporadic or heritable. Sixty to 70% of FTD cases are sporadic, while 30 to 40% are inherited (familial aggregation). For this study, blood samples were collected from clinically diagnosed or suspected FTD patients and were analysed for a broad range of pathogenic variants in genes associated with FTD. The scientific insights acquired from this study will help identify novel therapeutic targets and develop/ investigate potential disease-modifying drugs.

Interventions

DIAGNOSTIC_TESTGenetic Screening

Blood samples will be collected from clinically diagnosed or suspected FTD patients and will be analysed for a broad range of pathogenic variants in genes associated with FTD.

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

25 Years to 85 Years

Healthy volunteers

Yes

Inclusion criteria

* Informed consent, which includes reference to the genetic testing, is obtained from the participant/legal guardian * The participant is aged between 25 to 85 years * The participant is diagnosed with Frontotemporal dementia (FTD) or has signs or symptoms of FTD

Design outcomes

Primary

Measure	Time frame
To investigate the prevalence of genetic etiologies in FTD by genotyping FTD participants/ FTD suspected participants	15 months

Countries

Belgium, Germany, Greece, Italy, Portugal, Spain, Turkey (Türkiye)

Contacts

PRINCIPAL_INVESTIGATORPeter Bauer, Ph.D

Centogene GmbH

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 10, 2026